Novel Kyowa Kirin antibody progresses in lymphoma
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin's CCR4-targeting antibody KW-0761 has moved into Phase II development in Japan as a treatment for adult T-cell lymphoma.